Home ›
Lymphoma Trials ›
NCT05365659
IKS03 in Patients With Advanced B Cell Non-Hodgkin Lymphomas
This first-in-human study will evaluate the recommended dose for further clinical development, safety, tolerability, antineoplastic activity, immunogenicity, pharmacokinetics and pharmacodynamics of IKS03, a CD19 targeting antibody-drug conjugate, in patients with advanced B cell non-Hodgkin lymphoma (NHL).
Trial Details
NCT ID NCT05365659
Phase PHASE1
Sponsor Iksuda Therapeutics Ltd.
Status RECRUITING
Cancer Type Lymphoma
Interventions
Locations (sample) Baltimore, Maryland, United States|39.29038,-76.61219 Westmead, New South Wales, Australia|-33.80383,150.98768 Adelaide, South Australia, Australia|-34.92866,138.59863 Hobart, Tasmania, Australia|-42.87936,147.32941 Perth, Western Australia, Australia|-31.95224,115.8614
Key Eligibility Criteria
Males or females, ≥ 18 years of age Part I: documented B cell NHL (any subtype except Burkitt lymphoma, Waldenström macroglobulinemia, chronic lymphocytic leukemia); previously confir… Part II: documented B cell NHL (subtypes to be determined); confirmed CD19-positive; possible expansion cohorts may include: Diffuse large B cell lymphoma (including germinal center B cell type, activated B cell type)
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Lymphoma Trials on Trialify →